Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 4
1991 2
1992 4
1993 7
1994 7
1995 13
1996 6
1997 28
1998 25
1999 39
2000 61
2001 28
2002 55
2003 52
2004 40
2005 47
2006 71
2007 62
2008 84
2009 85
2010 101
2011 114
2012 100
2013 113
2014 97
2015 96
2016 91
2017 84
2018 73
2019 59
2020 64
2021 79
2022 78
2023 68
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

1,769 results

Results by year

Filters applied: . Clear all
Page 1
Pramipexole.
[No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000589 Free Books & Documents. Review.
No information is available on the use of pramipexole during breastfeeding, but it suppresses serum prolactin and may interfere with breastfeeding. ...
No information is available on the use of pramipexole during breastfeeding, but it suppresses serum prolactin and may interfere with …
Pramipexole.
[No authors listed] [No authors listed] 2017 Jul 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jul 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643301 Free Books & Documents. Review.
Pramipexole is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment, but has not been implicated in cases of clinically apparent acute …
Pramipexole is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associat …
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. ...CONCLUSION: This study suppo …
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ro …
Pramipexole.
Singh R, Parmar M. Singh R, et al. 2023 Apr 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Apr 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32491471 Free Books & Documents.
Pramipexole is a medication used in the management and treatment of Parkinsonism and restless leg syndrome. It is in the anti-parkinsonian class of drugs. This activity describes pramipexole's indications, action, and contraindications as a valuable agent in managin …
Pramipexole is a medication used in the management and treatment of Parkinsonism and restless leg syndrome. It is in the anti-parkins …
Classics in Chemical Neuroscience: Pramipexole.
Wilson SM, Wurst MG, Whatley MF, Daniels RN. Wilson SM, et al. ACS Chem Neurosci. 2020 Sep 2;11(17):2506-2512. doi: 10.1021/acschemneuro.0c00332. Epub 2020 Aug 17. ACS Chem Neurosci. 2020. PMID: 32786316 Review.
Pramipexole was first manufactured by Pharmacia and Upjohn in July 1997 under the United States brand names of Mirapex and Mirapex ER. ...Pramipexole is a unique compound in its therapeutic potential because it has D(3)-preferring properties. ...
Pramipexole was first manufactured by Pharmacia and Upjohn in July 1997 under the United States brand names of Mirapex and Mirapex ER …
[Pramipexole in bipolar depression: a literature review and clinical recommendations].
Dionys V, Sienaert P. Dionys V, et al. Tijdschr Psychiatr. 2021;63(9):658-664. Tijdschr Psychiatr. 2021. PMID: 34647304 Free article. Review. Dutch.
A second RCT reported higher response and remission results with pramipexole compared to placebo (60% vs. 9%, 40% vs. 9%). Pramipexole was generally well tolerated. CONCLUSION: The use of pramipexole in treatment resistant bipolar depression appears promising …
A second RCT reported higher response and remission results with pramipexole compared to placebo (60% vs. 9%, 40% vs. 9%). Pramipe …
Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE. Frampton JE. Drugs. 2014 Dec;74(18):2175-90. doi: 10.1007/s40265-014-0322-5. Drugs. 2014. PMID: 25385556 Review.
The two formulations are bioequivalent; the majority (>80 %) of patients can be switched overnight from pramipexole IR to ER without the need for dosage adjustment. In terms of improving activities of daily living and motor function in short-term (33-week), double-blind …
The two formulations are bioequivalent; the majority (>80 %) of patients can be switched overnight from pramipexole IR to ER witho …
Pramipexole extended release in Parkinson's disease.
Hametner EM, Seppi K, Poewe W. Hametner EM, et al. Expert Rev Neurother. 2011 Sep;11(9):1229-34. doi: 10.1586/ern.11.122. Expert Rev Neurother. 2011. PMID: 21864066 Review.
Pramipexole extended release (ER) is a new once-daily formulation of pramipexole, a nonergot dopamine agonist, which is available in five dosage strengths: 0.26 (0.375) mg, 0.52 (0.75) mg, 1.05 (1.5) mg, 2.1 (3) mg and 3.15 (4.5) mg (all doses are expressed in terms …
Pramipexole extended release (ER) is a new once-daily formulation of pramipexole, a nonergot dopamine agonist, which is availa …
Pramipexole for the treatment of early Parkinson's disease.
Perez-Lloret S, Rey MV, Ratti L, Rascol O. Perez-Lloret S, et al. Expert Rev Neurother. 2011 Jul;11(7):925-35. doi: 10.1586/ern.11.75. Expert Rev Neurother. 2011. PMID: 21721909 Review.
Pramipexole is a nonergolinic dopamine agonist, with high affinity for the D2 subfamily of dopamine receptors. ...Pramipexole can also improve depressive symptoms and possibly health-related quality of life in PD. ...
Pramipexole is a nonergolinic dopamine agonist, with high affinity for the D2 subfamily of dopamine receptors. ...Pramipexole …
Pramipexole extended release: in Parkinson's disease.
Chwieduk CM, Curran MP. Chwieduk CM, et al. CNS Drugs. 2010 Apr;24(4):327-36. doi: 10.2165/11204570-000000000-00000. CNS Drugs. 2010. PMID: 20297857 Review.
Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have similar exposure over 24 hours. ...Pramipexole ER was generally well tolerated in patients with Parkinson's disease, with the rate of adverse events being generally simila …
Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have similar exposure over 24 hours. ... …
1,769 results